NeuroOne's OneRF Trigeminal Nerve Ablation System Completes Limited Release; All 12 Patients Report Pain Freedom
Summary
NeuroOne Medical Technologies has successfully completed the limited market release of its OneRF Trigeminal Nerve Ablation System, treating 12 patients across three centers, all of whom reported freedom from pain. This positive operational milestone follows the FDA 510(k) clearance in August 2025 and is particularly significant given the company's recent financial challenges, including a going concern warning and Nasdaq delisting risk highlighted in its last 10-Q. The successful release, demonstrating strong clinical outcomes and procedural advantages like short treatment times and no need for patient repositioning, provides a crucial path towards potential revenue generation and improved financial stability. Investors should watch for updates on the company's plans to expand access to additional centers and pursue strategic partnership opportunities for broader commercialization.
At the time of this announcement, NMTC was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39M. The 52-week trading range was $0.40 to $1.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: EQS.